404 related articles for article (PubMed ID: 29893488)
1. Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo-controlled, double-blind, crossover trial.
Korsatko S; Jensen L; Brunner M; Sach-Friedl S; Tarp MD; Holst AG; Heller SR; Pieber TR
Diabetes Obes Metab; 2018 Nov; 20(11):2565-2573. PubMed ID: 29893488
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
3. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H
Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751
[TBL] [Abstract][Full Text] [Related]
4. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
[TBL] [Abstract][Full Text] [Related]
5. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
[TBL] [Abstract][Full Text] [Related]
7. Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.
Pieber TR; Deller S; Korsatko S; Jensen L; Christiansen E; Madsen J; Heller SR
Diabetes Obes Metab; 2015 Aug; 17(8):742-50. PubMed ID: 25855340
[TBL] [Abstract][Full Text] [Related]
8. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.
McCrimmon RJ; Catarig AM; Frias JP; Lausvig NL; le Roux CW; Thielke D; Lingvay I
Diabetologia; 2020 Mar; 63(3):473-485. PubMed ID: 31897524
[TBL] [Abstract][Full Text] [Related]
9. Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study.
Farngren J; Persson M; Ahrén B
Diabetes Obes Metab; 2018 Aug; 20(8):1911-1920. PubMed ID: 29645341
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
11. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J
JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653
[TBL] [Abstract][Full Text] [Related]
12. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity.
Hjerpsted JB; Flint A; Brooks A; Axelsen MB; Kvist T; Blundell J
Diabetes Obes Metab; 2018 Mar; 20(3):610-619. PubMed ID: 28941314
[TBL] [Abstract][Full Text] [Related]
13. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Frias JP; Deenadayalan S; Erichsen L; Knop FK; Lingvay I; Macura S; Mathieu C; Pedersen SD; Davies M
Lancet; 2023 Aug; 402(10403):720-730. PubMed ID: 37364590
[TBL] [Abstract][Full Text] [Related]
15. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
Rodbard HW; Lingvay I; Reed J; de la Rosa R; Rose L; Sugimoto D; Araki E; Chu PL; Wijayasinghe N; Norwood P
J Clin Endocrinol Metab; 2018 Jun; 103(6):2291-2301. PubMed ID: 29688502
[TBL] [Abstract][Full Text] [Related]
16. Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme.
DeVries JH; Desouza C; Bellary S; Unger J; Hansen OKH; Zacho J; Woo V
Diabetes Obes Metab; 2018 Oct; 20(10):2426-2434. PubMed ID: 29862621
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.
Kaku K; Yamada Y; Watada H; Abiko A; Nishida T; Zacho J; Kiyosue A
Diabetes Obes Metab; 2018 May; 20(5):1202-1212. PubMed ID: 29322610
[TBL] [Abstract][Full Text] [Related]
18. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.
Kapitza C; Dahl K; Jacobsen JB; Axelsen MB; Flint A
Diabetologia; 2017 Aug; 60(8):1390-1399. PubMed ID: 28526920
[TBL] [Abstract][Full Text] [Related]
19. Dose-response effects on HbA
Blüher M; Rosenstock J; Hoefler J; Manuel R; Hennige AM
Diabetologia; 2024 Mar; 67(3):470-482. PubMed ID: 38095657
[TBL] [Abstract][Full Text] [Related]
20. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
Nauck MA; Petrie JR; Sesti G; Mannucci E; Courrèges JP; Lindegaard ML; Jensen CB; Atkin SL;
Diabetes Care; 2016 Feb; 39(2):231-41. PubMed ID: 26358288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
